Asunto(s)
Dermatitis Atópica , Trastornos de Alimentación y de la Ingestión de Alimentos , Humanos , Dermatitis Atópica/epidemiología , Dermatitis Atópica/complicaciones , Estudios Transversales , Femenino , Masculino , Adulto , Adolescente , Trastornos de Alimentación y de la Ingestión de Alimentos/epidemiología , Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Adulto Joven , Estados Unidos/epidemiología , Niño , Persona de Mediana EdadRESUMEN
This case report describes a woman in her 40s with a medical history of systemic lupus erythematosus with 1 year of tender papules, plaques, and progressive ulcers on her hands and feet.
Asunto(s)
Lupus Eritematoso Sistémico , Vasculitis , Humanos , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/tratamiento farmacológico , Vasculitis/tratamiento farmacológico , Vasculitis/etiologíaAsunto(s)
Antineoplásicos , Inhibidores de las Cinasas Janus , Linfoma Cutáneo de Células T , Neoplasias Cutáneas , Humanos , Inhibidores de Proteasoma/farmacología , Inhibidores de Proteasoma/uso terapéutico , Inhibidores de las Cinasas Janus/uso terapéutico , Histona Desacetilasas , Linfoma Cutáneo de Células T/tratamiento farmacológico , Linfoma Cutáneo de Células T/patología , Inhibidores de Histona Desacetilasas/farmacología , Inhibidores de Histona Desacetilasas/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Proteínas Proto-Oncogénicas c-bcl-2 , Línea Celular Tumoral , Antineoplásicos/uso terapéuticoRESUMEN
The incidence of cutaneous T-cell lymphoma (CTCL) increases with age, and blood involvement portends a worse prognosis. To advance our understanding of the development of CTCL and identify potential therapeutic targets, we performed integrative analyses of paired single-cell RNA and T-cell receptor (TCR) sequencing of peripheral blood CD4+ T cells from patients with CTCL to reveal disease-unifying features. The malignant CD4+ T cells of CTCL showed highly diverse transcriptomic profiles across patients, with most displaying a mature Th2 differentiation and T-cell exhaustion phenotype. TCR-CDR3 peptide prediction analysis suggested limited diversity between CTCL samples, consistent with a role for a common antigenic stimulus. Potential of heat diffusion for affinity-based trajectory embedding transition analysis identified putative precancerous circulating populations characterized by an intermediate stage of gene expression and mutation level between the normal CD4+ T cells and malignant CTCL cells. We further revealed the therapeutic potential of targeting CD82 and JAK that endow the malignant CTCL cells with survival and proliferation advantages.
Asunto(s)
Linfoma Cutáneo de Células T , Neoplasias Cutáneas , Humanos , Transcriptoma , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patología , Linfoma Cutáneo de Células T/patología , Linfocitos T CD4-Positivos/metabolismo , Receptores de Antígenos de Linfocitos T/genéticaRESUMEN
Acute colonic pseudo-obstruction, also known as Ogilvie's syndrome, is a rare condition involving acute large bowel dilatation without mechanical obstruction. Management begins with conservative treatment and may include pharmacological therapy, colonoscopic decompression and surgery. Timely resolution is important due to the increased risk of bowel perforation and ischaemia associated with colonic dilatation. However, conditions such as neutropenia that place patients at an elevated risk of infection may limit treatment options. We report a case of acute colonic pseudo-obstruction in a neutropenic elderly man resistant to conservative measures and neostigmine and discuss the additional management considerations in an immunocompromised patient.
Asunto(s)
Seudoobstrucción Colónica , Neutropenia , Anciano , Seudoobstrucción Colónica/complicaciones , Seudoobstrucción Colónica/terapia , Colonoscopios , Humanos , Masculino , Neostigmina/uso terapéuticoRESUMEN
Chronic ultraviolet (UV) radiation exposure is the greatest risk factor for cutaneous squamous cell carcinoma (cSCC) development, and compromised immunity accelerates this risk. Having previously identified that epidermal Langerhans cells (LC) facilitate the expansion of UV-induced mutant keratinocytes (KC), we sought to more fully elucidate the immune pathways critical to cutaneous carcinogenesis and to identify potential targets of intervention. Herein, we reveal that chronic UV induces and LC enhance a local immune shift toward RORγt+ interleukin (IL)-22/IL-17A-producing cells that occurs in the presence or absence of T cells while identifying a distinct RORγt+ Sca-1+ CD103+ ICOS+ CD2+/- CCR6+ intracellular CD3+ cutaneous innate lymphoid cell type-3 (ILC3) population (uvILC3) that is associated with UV-induced mutant KC growth. We further show that mutant KC clone size is markedly reduced in the absence of RORγt+ lymphocytes or IL-22, both observed in association with expanding KC clones, and find that topical application of a RORγ/γt inhibitor during chronic UV exposure reduces local expression of IL-22 and IL-17A while markedly limiting mutant p53 KC clonal expansion. We implicate upstream Toll-like receptor signaling in driving this immune response to chronic UV exposure, as MyD88/Trif double-deficient mice also show substantially reduced p53 island number and size. These data elucidate key immune components of chronic UV-induced cutaneous carcinogenesis that might represent targets for skin cancer prevention.
Asunto(s)
Interleucinas/metabolismo , Queratinocitos/patología , Linfocitos/patología , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo , Neoplasias Cutáneas/patología , Piel/patología , Rayos Ultravioleta/efectos adversos , Animales , Carcinogénesis/metabolismo , Carcinogénesis/patología , Carcinogénesis/efectos de la radiación , Células Cultivadas , Inmunidad Innata/inmunología , Interleucinas/genética , Queratinocitos/metabolismo , Queratinocitos/efectos de la radiación , Células de Langerhans/inmunología , Células de Langerhans/metabolismo , Células de Langerhans/patología , Células de Langerhans/efectos de la radiación , Linfocitos/inmunología , Linfocitos/metabolismo , Linfocitos/efectos de la radiación , Ratones , Mutación , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/genética , Piel/metabolismo , Piel/efectos de la radiación , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/metabolismo , Interleucina-22RESUMEN
INTRODUCTION: The most common types of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS). In both MF and SS, complete responses to treatment are uncommon. Recent developments and understanding of the biology of MF/SS have led to novel agents which may offer prolonged responses with less toxicity compared to conventional chemotherapy approaches. AREAS COVERED: In this review, we discuss the efficacy and safety of new nonchemotherapy treatment options including antibody agents, small molecule inhibitors, fusion proteins, and CAR T-cell therapy. We also reflect on older immunomodulatory treatments including retinoids and histone deacetylase inhibitors. EXPERT OPINION: Patients with MF/SS who require systemic therapy often progress through multiple agents sequentially, thus the need for additional novel agents in the treatment armamentarium. Antibody-based therapies such as alemtuzumab are highly effective in the blood compartment of disease, while brentuximab vedotin has shown higher activity in skin and lymph nodes. Checkpoint inhibitors may play a role in treating MF/SS but may induce hyperprogression, and engineered T cells and bispecific antibodies recruiting immune effectors are being developed and may show promise in the future.